This invention discloses a novel strategy to reprogram either allogenic or heterologous peripheral blood neutrophils and/or monocytes with a selective compound in vitro, into a homeostatic state that is conducive for healing of coronary heart disease and/or stroke. Reprogrammed monocytes and/or neutrophils can be used through i.v. injection into human patients for therapeutic treatment.
